Koo Ja-Hyun, Kim Gil-Ran, Nam Kyung-Ho, Choi Je-Min
Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea; The Ragon Institute of Massachusetts General Hospital, Massachusetts Institute of Technology and Harvard University, Cambridge, MA 02139, USA.
Department of Life Science, College of Natural Sciences, Hanyang University, Seoul 04763, Republic of Korea.
Trends Mol Med. 2022 Jun;28(6):482-496. doi: 10.1016/j.molmed.2022.03.010. Epub 2022 Apr 21.
With the advent of cancer immunotherapy, immunomodulation has emerged as an important strategy for the treatment of various diseases. We review recent advances in clinical trials of cell-penetrating peptide (CPP) applications for immunotherapy and also discuss their challenges and opportunities for preclinical studies in various immune diseases. CPP conjugation to antigenic peptides or proteins can enable efficient antigen uptake and cross-presentation by antigen-presenting cells (APCs), which induce both humoral and cytotoxic responses. In addition, CPP-coupled immune modulators can enhance antitumor immunity or anti-inflammatory effects to regulate allergies and autoimmunity. Given their huge advantages in overcoming delivery barriers, CPP-based strategies for immunomodulation could extend drug optimization and advance immunotherapy in various human diseases.
随着癌症免疫疗法的出现,免疫调节已成为治疗各种疾病的重要策略。我们综述了细胞穿透肽(CPP)应用于免疫疗法的临床试验的最新进展,并讨论了其在各种免疫疾病临床前研究中的挑战和机遇。将CPP与抗原肽或蛋白质偶联可使抗原呈递细胞(APC)有效摄取抗原并进行交叉呈递,从而诱导体液免疫和细胞毒性反应。此外,CPP偶联的免疫调节剂可增强抗肿瘤免疫力或抗炎作用,以调节过敏和自身免疫。鉴于其在克服递送障碍方面的巨大优势,基于CPP的免疫调节策略可扩展药物优化并推动各种人类疾病的免疫治疗发展。